Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

TANG Yuan, LI Zhi-quan, LIU Man-ying. Study on 100 cases of adverse reactions of aripipirazole tablets[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(2): 149-151.
Citation: TANG Yuan, LI Zhi-quan, LIU Man-ying. Study on 100 cases of adverse reactions of aripipirazole tablets[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(2): 149-151.

Study on 100 cases of adverse reactions of aripipirazole tablets

  • Received Date: 2010-06-10
  • Rev Recd Date: 2010-12-06
  • Objective To analyze the characteristics of adverse drug reactions (ADR) induced by aripipirazole tablets. Methods The reports of ADRs published during 2002~2008 induced by aripipirazole tablets were studied. Results Primary symptoms of ADRs induced by aripipirazole tablets were headache, sleeplessness, anxious, sick,vomiting, hypersomnia, intense and cathisophobia, which were usually occurred in 1~2 weeks. conclusion ADRs induced by aripipirazole tablets have multiple factors which should be highly concerned in clinical use.
  • [1] Burris KD, Molski TF,Xu C,et al. Aripipirazole,a novel antipsychotic,is a high-affinity partial agonist at human dopamine D2 receptors[J].J Pharmacol Exp Ther,2002,302:381.
    [2] Inoue A,Nakata Y.Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy[J].Jpn J Pharmacol,2001,86:376.
    [3] Lieberman JA.Dopamine partial agonists:a new class of antipsychotic[J].CNS Drugs,2004,18(4):251.
    [4] Marder SR,McQuade RD,Stock E. Aripipirazole in the treatment of schizophrenia:safety and tolerability in the treatment of schizophrenia: safety and tolerability in the short-term,placebocontrolled trials[J].Schizophr Res,2003,1916:1.
    [5] Logue DD,Gonzalez N,Heligman SD,et al.Hyperglycemia in a 7-year-old child treeyed with Aripipirazole[J].Am J Psychiatry,2007,164(1):173.
    [6] Newcomer JW,Haupt DW. The metabolic effects of antipsychotic medications[J].Can J Psychiatry,2006,51:480.
    [7] McQuade RD,Stock E,Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripipirazole:results from a randomized,double-blind study[J].J Clin Psychiatry,2004,65(Suppl 18):47.
    [8] ADA.Consensus development conference on antipsychotic drugs and obesity and diabetes (American Diabetes Association; American Psychiatric Association; American Association of clinical Endocrinologists;North American Association for the study of obesity)[J].Diabetes Care,2004,27:596.
    [9] De Hert M,Hanssens L,Winkel R, et al. A case series:evaluation of the metabolic safety of aripipirazole[J]. Schizophr,2007,33:823.
    [10] Olfson M,Marcus SC,Corey-Lisle P,Hyperlipidemia forlowing treatment with antipsychotic medications[J].Am J Psychiatry,2006,163:1821.
    [11] Lee BH,Kim YK,Park SH.Using aripipirazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study Prog Neuropsychopharmacol Biol Psychiatry[J]. 2006,30:714.
    [12] Anghelescu I,Wolf J.Successful switch to aripipirazole after induction of hyperprolactinemia by ziprasidone:a case report[J].J Clin Psychiatry,2004,65:1286.
    [13] Hanssens L,L Italien G,Marcus R, et al. Sexual dysfunction in naturalistic,open-label study of aripipirazole and standard-of-care in community-treated patients with schizophrenia(the STAR trial)[C].Toronto,Canada: American Psychiatric Association 159th annual meeting.2006.
    [14] Abilify Summary of Product Characteristics[C].London:Otsuka Pharmaceutical Europe Ltd;2006.
    [15] Oosterhuis M, Van De Kraats G,Tenback D.Safety of Aripipirazole:high serum levels in a CYP2D6 mutated patient[J].Am J Psychiatry,2007,164(1):175.
    [16] Spina E,de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review[J].Basic Clin Pharmacol Toxicol,2007,100(1):4.
    [17] Kan JM, Carson WH, Saha AR, et al. Efficacy and safety of aripipirazole and haloperidol versus placebo in patients with schizophrenia and schizophrenia disorder[J]. JClin Psychiatry,2002,63:763.
    [18] Keck PE, Jr, McElroy SL. Aripipirazole: a partial dopamine D2 receptor agonist antipsychotic[J].Expert Opin Investig Drugs,2003,12:655.
    [19] De Hert M,Hanssens L,van Winkel R, et al.Reversibility of antipschotic treament-related diabetes in patients with schizophrenia:a case of switching to aripipirazole[J]. Diabetes Care,2006,29:2329.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(2701) PDF downloads(127) Cited by()

Related
Proportional views

Study on 100 cases of adverse reactions of aripipirazole tablets

Abstract: Objective To analyze the characteristics of adverse drug reactions (ADR) induced by aripipirazole tablets. Methods The reports of ADRs published during 2002~2008 induced by aripipirazole tablets were studied. Results Primary symptoms of ADRs induced by aripipirazole tablets were headache, sleeplessness, anxious, sick,vomiting, hypersomnia, intense and cathisophobia, which were usually occurred in 1~2 weeks. conclusion ADRs induced by aripipirazole tablets have multiple factors which should be highly concerned in clinical use.

TANG Yuan, LI Zhi-quan, LIU Man-ying. Study on 100 cases of adverse reactions of aripipirazole tablets[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(2): 149-151.
Citation: TANG Yuan, LI Zhi-quan, LIU Man-ying. Study on 100 cases of adverse reactions of aripipirazole tablets[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(2): 149-151.
Reference (19)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return